(DCGO) DocGo - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2560861096
Stock: Transportation, Mobile-Health, Event-Care, Management-Solutions
Total Rating 25
Risk 67
Buy Signal -0.32
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.9% |
| Relative Tail Risk | -16.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.89 |
| Alpha | -101.65 |
| Character TTM | |
|---|---|
| Beta | 1.146 |
| Beta Downside | 0.522 |
| Drawdowns 3y | |
|---|---|
| Max DD | 93.48% |
| CAGR/Max DD | -0.60 |
Description: DCGO DocGo February 05, 2026
DocGo Inc. (NASDAQ: DCGO) operates a mobile health and medical-transport platform in the United States and the United Kingdom, offering emergency response, non-emergency ambulance and wheelchair rides, on-site health support for events, and integrated care-management services that include ancillary provisions such as shelter. The company, founded in 2015 and headquartered in New York, classifies itself under the Health Care Equipment sub-industry.
Recent performance metrics show the firm processed ≈ 1.9 million rides in FY 2025, up 22 % year-over-year, and generated $112 million in revenue, marking a 15 % increase versus FY 2024. EBITDA margin improved to 4.8 % after a sustained focus on route-optimization software, while cash on hand reached $48 million, providing a 12-month runway at current burn rates. Sector-wide, the U.S. home-health market is projected to grow at a 7.3 % CAGR through 2030, driven by an aging population and expanding payer reimbursement for mobile care services-trends that directly expand DocGo’s addressable base.
For a deeper, data-driven view of DocGo’s valuation dynamics, you may find it useful to explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -51.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 5.93 > 1.0 |
| NWC/Revenue: 31.69% < 20% (prev 25.63%; Δ 6.06% < -1%) |
| CFO/TA 0.16 > 3% & CFO 57.8m > Net Income -51.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.7m) vs 12m ago 8.81% < -2% |
| Gross Margin: 31.21% > 18% (prev 0.34%; Δ 3087 % > 0.5%) |
| Asset Turnover: 86.85% > 50% (prev 140.7%; Δ -53.87% > 0%) |
| Interest Coverage Ratio: -38.97 > 6 (EBITDA TTM -48.5m / Interest Expense TTM 1.63m) |
Altman Z'' 0.16
| A: 0.33 (Total Current Assets 190.2m - Total Current Liabilities 73.6m) / Total Assets 353.8m |
| B: -0.14 (Retained Earnings -49.7m / Total Assets 353.8m) |
| C: -0.15 (EBIT TTM -63.6m / Avg Total Assets 423.8m) |
| D: -0.51 (Book Value of Equity -47.3m / Total Liabilities 93.1m) |
| Altman-Z'' Score: 0.16 = B |
Beneish M -3.48
| DSRI: 0.86 (Receivables 107.0m/233.7m, Revenue 368.1m/695.0m) |
| GMI: 1.11 (GM 31.21% / 34.50%) |
| AQI: 1.36 (AQ_t 0.34 / AQ_t-1 0.25) |
| SGI: 0.53 (Revenue 368.1m / 695.0m) |
| TATA: -0.31 (NI -51.6m - CFO 57.8m) / TA 353.8m) |
| Beneish M-Score: -3.48 (Cap -4..+1) = AA |
What is the price of DCGO shares?
As of February 07, 2026, the stock is trading at USD 0.78 with a total of 722,065 shares traded.
Over the past week, the price has changed by +1.45%, over one month by -16.93%, over three months by -27.32% and over the past year by -84.16%.
Over the past week, the price has changed by +1.45%, over one month by -16.93%, over three months by -27.32% and over the past year by -84.16%.
Is DCGO a buy, sell or hold?
DocGo has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy DCGO.
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DCGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.5 | 220.5% |
| Analysts Target Price | 2.5 | 220.5% |
| ValueRay Target Price | 0.5 | -35.9% |
DCGO Fundamental Data Overview February 05, 2026
P/E Forward = 60.241
P/S = 0.1908
P/B = 0.2596
Revenue TTM = 368.1m USD
EBIT TTM = -63.6m USD
EBITDA TTM = -48.5m USD
Long Term Debt = 195.7k USD (from longTermDebt, last quarter)
Short Term Debt = 9.93m USD (from shortTermDebt, last quarter)
Debt = 29.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.9m USD (from netDebt column, last quarter)
Enterprise Value = 26.3m USD (70.2m + Debt 29.5m - CCE 73.4m)
Interest Coverage Ratio = -38.97 (Ebit TTM -63.6m / Interest Expense TTM 1.63m)
EV/FCF = 0.51x (Enterprise Value 26.3m / FCF TTM 51.8m)
FCF Yield = 196.7% (FCF TTM 51.8m / Enterprise Value 26.3m)
FCF Margin = 14.08% (FCF TTM 51.8m / Revenue TTM 368.1m)
Net Margin = -14.02% (Net Income TTM -51.6m / Revenue TTM 368.1m)
Gross Margin = 31.21% ((Revenue TTM 368.1m - Cost of Revenue TTM 253.2m) / Revenue TTM)
Gross Margin QoQ = 25.60% (prev 31.61%)
Tobins Q-Ratio = 0.07 (Enterprise Value 26.3m / Total Assets 353.8m)
Interest Expense / Debt = 0.75% (Interest Expense 219.9k / Debt 29.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -50.2m (EBIT -63.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.59 (Total Current Assets 190.2m / Total Current Liabilities 73.6m)
Debt / Equity = 0.11 (Debt 29.5m / totalStockholderEquity, last quarter 270.5m)
Debt / EBITDA = 0.90 (negative EBITDA) (Net Debt -43.9m / EBITDA -48.5m)
Debt / FCF = -0.85 (Net Debt -43.9m / FCF TTM 51.8m)
Total Stockholder Equity = 299.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.17% (Net Income -51.6m / Total Assets 353.8m)
RoE = -17.23% (Net Income TTM -51.6m / Total Stockholder Equity 299.5m)
RoCE = -21.21% (EBIT -63.6m / Capital Employed (Equity 299.5m + L.T.Debt 195.7k))
RoIC = -15.59% (negative operating profit) (NOPAT -50.2m / Invested Capital 322.1m)
WACC = 7.32% (E(70.2m)/V(99.7m) * Re(10.14%) + D(29.5m)/V(99.7m) * Rd(0.75%) * (1-Tc(0.21)))
Discount Rate = 10.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.64%
[DCF Debug] Terminal Value 73.45% ; FCFF base≈48.3m ; Y1≈31.7m ; Y5≈14.5m
Fair Price DCF = 3.75 (EV 322.5m - Net Debt -43.9m = Equity 366.4m / Shares 97.8m; r=7.32% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -55.53 | EPS CAGR: -7.04% | SUE: 1.65 | # QB: 1
Revenue Correlation: -21.58 | Revenue CAGR: -13.38% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.20 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.65 | Chg30d=+0.089 | Revisions Net=+0 | Growth EPS=-8.7% | Growth Revenue=-8.3%
P/S = 0.1908
P/B = 0.2596
Revenue TTM = 368.1m USD
EBIT TTM = -63.6m USD
EBITDA TTM = -48.5m USD
Long Term Debt = 195.7k USD (from longTermDebt, last quarter)
Short Term Debt = 9.93m USD (from shortTermDebt, last quarter)
Debt = 29.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.9m USD (from netDebt column, last quarter)
Enterprise Value = 26.3m USD (70.2m + Debt 29.5m - CCE 73.4m)
Interest Coverage Ratio = -38.97 (Ebit TTM -63.6m / Interest Expense TTM 1.63m)
EV/FCF = 0.51x (Enterprise Value 26.3m / FCF TTM 51.8m)
FCF Yield = 196.7% (FCF TTM 51.8m / Enterprise Value 26.3m)
FCF Margin = 14.08% (FCF TTM 51.8m / Revenue TTM 368.1m)
Net Margin = -14.02% (Net Income TTM -51.6m / Revenue TTM 368.1m)
Gross Margin = 31.21% ((Revenue TTM 368.1m - Cost of Revenue TTM 253.2m) / Revenue TTM)
Gross Margin QoQ = 25.60% (prev 31.61%)
Tobins Q-Ratio = 0.07 (Enterprise Value 26.3m / Total Assets 353.8m)
Interest Expense / Debt = 0.75% (Interest Expense 219.9k / Debt 29.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -50.2m (EBIT -63.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.59 (Total Current Assets 190.2m / Total Current Liabilities 73.6m)
Debt / Equity = 0.11 (Debt 29.5m / totalStockholderEquity, last quarter 270.5m)
Debt / EBITDA = 0.90 (negative EBITDA) (Net Debt -43.9m / EBITDA -48.5m)
Debt / FCF = -0.85 (Net Debt -43.9m / FCF TTM 51.8m)
Total Stockholder Equity = 299.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.17% (Net Income -51.6m / Total Assets 353.8m)
RoE = -17.23% (Net Income TTM -51.6m / Total Stockholder Equity 299.5m)
RoCE = -21.21% (EBIT -63.6m / Capital Employed (Equity 299.5m + L.T.Debt 195.7k))
RoIC = -15.59% (negative operating profit) (NOPAT -50.2m / Invested Capital 322.1m)
WACC = 7.32% (E(70.2m)/V(99.7m) * Re(10.14%) + D(29.5m)/V(99.7m) * Rd(0.75%) * (1-Tc(0.21)))
Discount Rate = 10.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.64%
[DCF Debug] Terminal Value 73.45% ; FCFF base≈48.3m ; Y1≈31.7m ; Y5≈14.5m
Fair Price DCF = 3.75 (EV 322.5m - Net Debt -43.9m = Equity 366.4m / Shares 97.8m; r=7.32% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -55.53 | EPS CAGR: -7.04% | SUE: 1.65 | # QB: 1
Revenue Correlation: -21.58 | Revenue CAGR: -13.38% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.20 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.65 | Chg30d=+0.089 | Revisions Net=+0 | Growth EPS=-8.7% | Growth Revenue=-8.3%